UBI集團訊息
UBI集團訊息
-
View More 聯亞生技受食藥署邀請演講 ： 國際蛋白質藥物發展趨勢
-
View More 
UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing FacilityUBI集團訊息UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing Facility
UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing Facility -
-
-
View More 
United BioPharma Closes A Fundraising of NT$ 500 MillionUBI集團訊息United BioPharma Closes A Fundraising of NT$ 500 Million
United BioPharma Closes A Fundraising of NT$ 500 Million -
View More 
United BioPharma to establish industrial protein drug manufacturing process via ICP programUBI集團訊息United BioPharma to establish industrial protein drug manufacturing process via ICP program
United BioPharma to establish industrial protein drug manufacturing process via ICP program -
View More 工業合作案引進蛋白質藥物量產技術 促進國內生技製藥產業升級 是一大突破
-
View More 
United BioPharma Receives Technology Enterprise Qualification Planning for IPO soonUBI集團訊息United BioPharma Receives Technology Enterprise Qualification Planning for IPO soon
United BioPharma Receives Technology Enterprise Qualification Planning for IPO soon -
View More 
UBP Presents at Antibody Drug Development Conference Plans to submit Phase I Clinical Trial application in 2017 for UB-221, a third-generation anti-IgE monoclonal antibody drugUBI集團訊息UBP Presents at Antibody Drug Development Conference Plans to submit Phase I Clinical Trial application in 2017 for UB-221, a third-generation anti-IgE monoclonal antibody drug
UBP Presents at Antibody Drug Development Conference Plans to submit Phase I Clinical Trial application in 2017 for UB-221, a third-generation anti-IgE monoclonal antibody drug -
-
View More 
Drug Holiday is not just a dream! United BioPharma announced positive result in UB-421 Phase II Clinical TrialUBI集團訊息Drug Holiday is not just a dream! United BioPharma announced positive result in UB-421 Phase II Clinical Trial
Drug Holiday is not just a dream! United BioPharma announced positive result in UB-421 Phase II Clinical Trial -
View More 105年度生技產業暨投資論壇-聯合生物製藥股份有限公司
-
-
View More 
我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！ -
View More 
我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力–我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力– -
View More 
我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏
TAG相關標籤
POPULAR熱門文章
